Table 3.

Subgroup analysis of complications between LCVP and control group.

Subgroup	Study	Case (n/N)		Heterogeneity		Effect size
		LCVP	Control	I 2	P	RR(95% CI)	P
Diagnosis
Chest infection	[14, 18–20, 23, 25]	20/283	37/327	0%	0.96	0.56 (0.35, 0.90)	0.02
Pleural effusion	[14, 18–20, 23, 25]	41/283	57/327	43%	0.12	0.72 (0.51, 1.02)	0.06
Wound infection	[14, 23]	5/120	7/111	0%	0.75	0.64 (0.21, 1.93)	0.43
Ascites	[14, 18, 23]	12/140	22/169	0%	0.81	0.56 (0.29, 1.08)	0.08
Heart disorder	[18, 20]	1/87	2/141	0%	0.40	1.36 (0.19, 9.67)	0.76
Bile leakage	[18, 20]	2/80	2/111	0%	0.75	1.41 (0.22, 9.23)	0.72
Bleeding	[18, 20]	0/80	3/111	0%	0.45	0.35 (0.05, 2.67)	0.31
Hepatic insufficiency	[18, 20]	3/80	5/111	0%	0.49	0.90 (0.21, 3.85)	0.88
Sepsis	[18, 20]	3/103	4/101	0%	0.33	0.77 (0.20, 3.02)	0.71
Methods
IVCC versus control	[14, 18, 20, 23]	52/207	69/252	0%	0.50	0.83 (0.62, 1.11)	0.2
IAC versus control	[15, 19, 25]	47/101	68/100	0%	0.70	0.68 (0.55, 0.86)	0.009
Total
LCVP versus control	[14, 15, 18–20, 23, 25]	99/308	137/352	0%	0.71	0.75 (0.63, 0.91)	0.003